Related Experiment Video
Updated: Jul 31, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Delayed Injection Site Reaction to Fremanezumab for Chronic Migraine Treatment
Kevin V Thomas1, Daniel D Bennett1, Justin Endo2
1University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Introduction:
Fremanezumab is a humanized monoclonal antibody administered through a subcutaneous injection. It is used for treatment of migraines, and occasional injection site reactions have developed after usage.
Case Presentation:
This case report describes a nonimmediate injection site reaction on the right thigh of a 25-year-old female patient after starting treatment with fremanezumab. The injection site reaction presented as 2 warm, red annular plaques 8 days following a second injection of fremanezumab and about 5 weeks following the first injection. She was prescribed a 1-month course of prednisone that relieved her symptoms of redness, itching, and pain.
Discussion:
Similar nonimmediate injection site reactions have been reported before, but this particular injection site reaction was significantly more delayed.
Conclusions:
Our case illustrates that injection site reactions to fremanezumab can be delayed after the second dose and may require systemic therapy to alleviate symptoms.
More Related Videos
Related Concept Videos
Allergic Drug Reactions
Desensitization and Tachyphylaxis
Local Anesthetics: Adverse Effects
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

